Most of the posting here has dealt with the basics of our progress or lack thereof in our efforts of discovery and well it should be but let me offer another side of the coin from a short term point of view affecting our stock price. If you will for the moment forget the medical jargon and concentrate just on the age old habits of the market place which has taken us to these levels. I use INO as part of my argument and not because it is a twin to ONCS. INO announced their intent to issue a r/v of 1/4 and that has yet to occur but is over-hanging the market. ONCS rumors are plentiful on the same subject and thus placing a cloud on price performance. INO released their EPS which was below expectations in dollars and cents which conforms to the figures just released by ONCS showing the loss has doubled from the same like period to 8 plus mill. from 4.5mill. I could go on but please consider these and other like similarities and look at the charts for both companies in the month of June. Both charts speak of what we already know. This is the nature of the beast, markets do this despite the fact that in both companies in the testing/medical area they continue to be promising.. Your decision to buy or sell should be an informed one and consider those elements that are affecting our stock price whether you want to hear them or not, it's your money. Have a good day.
Do you realize that the new issue added $.063 to the book value of your shares after the date of the financials? Earnings per share were negative $.05 and decreased the book value of your shares by that much prior to the new issue.
"I use INO as part of my argument and not because it is a twin to ONCS. INO announced their intent to issue a r/v of 1/4 and that has yet to occur but is over-hanging the market. "....
WHY are you saying INO is a twin to ONCS? strange.
WHY are you saying INO announced an intent to issue a 1/4 rs whenthat has already happened. double strange.